Single-Agent Tislelizumab, an Anti-PD-1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients

被引：1

作者：

Barlow, P. ^{[1
]}

Jameson, M. ^{[2
,3
]}

Lin, C. ^{[4
]}

Wu, J. ^{[5
]}

Pirzkall, A. ^{[5
]}

Lee, J. ^{[6
]}

机构：

[1] Auckland City Hosp, Auckland, New Zealand

[2] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand

[3] Univ Auckland, Waikato Clin Campus, Hamilton, New Zealand

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Beigene Usa Inc, San Mateo, CA USA

[6] Seoul Natl Univ, Bundang Hosp, Seongnam Si, Gyeonggi Do, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

tislelizumab; NSCLC; Anti-PD-1;

D O I：

10.1016/j.jtho.2019.08.1538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.04-33

引用

页码：S721 / S721

页数：1

共 50 条

[31] First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+locally advanced or metastatic urothelial carcinoma (UC) in Asian patients
Ye, D.
Liu, J.
Zhou, A.
Zou, Q.
Li, H.
Fu, C.
Hu, H.
Huang, J.
Zhu, S.
Jin, J.
Ma, L.
Guo, J.
Xiao, J.
Park, S. H.
Zhang, D.
Qiu, X.
Bao, Y.
Zhang, L.
Shen, W.
Feng, B.
ANNALS OF ONCOLOGY, 2019, 30 : 367 - 367
[32] Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients
Huang, Y.
Soon, Y. Y.
Aminkeng, F.
Tay, S. H.
Ang, Y.
Goh, B. C.
Wong, A.
Soo, R. A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S577 - S577
[33] Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study
Desai, Jayesh
Markman, Benjamin
Friedlander, Michael
Gan, Hui
Horvath, Lisa
Townsend, Amanda
Millward, Michael
Jameson, Michael
Yen, Chia-Jui
Hou, Ming-Mo
Hou, Jeannie
Wu, John
Liang, Liang
Deva, Sanjeev
CANCER RESEARCH, 2019, 79 (13)
[34] Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Ducreux, M.
Abou-Alfa, G.
Ren, Z.
Edeline, J.
Li, Z.
Assenat, E.
Rimassa, L.
Blanc, J.
Ross, P.
Fang, W.
Hu, S.
Zhang, T.
Tran, A.
Pan, H.
Yen, C.
Wu, J.
Li, V.
Chica-Duque, S.
Merle, P.
Cheng, A.
ANNALS OF ONCOLOGY, 2021, 32 : S217 - S217
[35] Cancer derived blood exosomes are potential predictive biomarkers for NSCLC patients treated with anti-PD-1 antibody
Ohta, Shigeki
Kinoshita, Tomonar
Wakui, Seiki
Maeda, Chihaya
Hayashi, Yuichiro
Misawa, Aya
Satomi, Ryosuke
Ikemura, Shinnosuke
Soejima, Kenzo
Yaguchi, Tomonori
Kagamu, Hiroshi
Kawakami, Yutaka
CANCER SCIENCE, 2024, 115 : 1383 - 1383
[36] Plasma exosome subsets are potential predictive biomarkers for NSCLC patients treated with anti-PD-1 antibody or surgery
Ohta, Shigeki
Kinoshita, Tomonari
Wakui, Seiki
Maeda, Chihaya
Hayashi, Yuichiro
Yaguchi, Tomonori
Kagamu, Hiroshi
Kawakami, Yutaka
CANCER SCIENCE, 2023, 114 : 1987 - 1987
[37] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Yamamoto, Noboru
Nokihara, Hiroshi
Yamada, Yasuhide
Shibata, Takashi
Tamura, Yosuke
Seki, Yoshitaka
Honda, Kazunori
Tanabe, Yuko
Wakui, Hiroshi
Tamura, Tomohide
INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
[38] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Noboru Yamamoto
Hiroshi Nokihara
Yasuhide Yamada
Takashi Shibata
Yosuke Tamura
Yoshitaka Seki
Kazunori Honda
Yuko Tanabe
Hiroshi Wakui
Tomohide Tamura
Investigational New Drugs, 2017, 35 : 207 - 216
[39] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Mengke Niu
Ming Yi
Ning Li
Suxia Luo
Kongming Wu
Experimental Hematology & Oncology, 10
[40] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, Mengke
Yi, Ming
Li, Ning
Luo, Suxia
Wu, Kongming
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)

← 1 2 3 4 5 →